Unionville Capital

Unionville Capital is a private healthcare-focused investment and company-building firm based in New Jersey. Publicly available information indicates it formed Sauvie in 2022 to develop and commercialize immuno-oncology therapies, including licensed nanobody-based natural killer cell engager technology from Rutgers. The entity appears to function more as a sponsor, holding company, or incubator than as a standalone drug developer with an independently disclosed pipeline. Its visible healthcare activity is centered on oncology opportunity creation, strategic partnerships, and portfolio formation rather than broad operating biopharma infrastructure. Because disclosures are limited, most therapeutic and pipeline information attributable to Unionville Capital is inferred through its formation and control of Sauvie.